ScreenerHero

BCAX Bicara Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · bicara.com
16.42USD-0.85%Mkt Cap: 1.09B $P/E: —

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a cl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.09B USD
Enterprise Value599.73M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-137.95M USD
Revenue/Share—
Last Price16.42 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees103
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.71
PEG—
EV/EBITDA-2.97
EV/Revenue—
P/S—
P/B2.33
EPS (TTM)-2.95
EPS (Forward)-3.52
52W Range
13.7016% of range30.99
52W High30.99 USD
52W Low13.70 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.36%
ROA-32.01%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-106.83M USD
CapEx (TTM)280.00K USD
FCF Margin—
FCF Yield-7.08%
Net Debt-496.10M USD
Net Debt/EBITDA2.46
Balance Sheet
Debt/Equity0.00
Current Ratio11.59
Quick Ratio11.44
Book Value/Sh7.11 USD
Cash/Share7.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.50 USD
Upside (mean)+116.2%
Target Range20.00 USD – 45.00 USD
20.00+116.2% to mean45.00
# Analysts12
Ownership
Shares Out.66.17M
Float36.90M
Insiders10.07%
Institutions107.64%
Short Interest
Short Ratio22.4d
Short % Float23.56%
Short % Out.16.91%
Shares Short11.19M
Short (prev mo.)10.46M
Technical
SMA 5023.46 (-30.0%)
SMA 20021.31 (-22.9%)
Beta-0.69
S&P 52W Chg16.45%
Avg Vol (30d)645.22K
Avg Vol (10d)799.60K
Technical Indicators
RSI (14)20.2
MACD-1.8626
MACD Signal-1.5388
MACD Hist.-0.3239
BB Upper25.08 USD
BB Middle20.27 USD
BB Lower15.45 USD
BB Width47.51%
ATR (14)1.212 USD
Vol Ratio (20d)1.28x